Clinical Cancer Research CR Surrogrates Advances in Breast Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Solit, D. B.
Right arrow Articles by Rosen, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Solit, D. B.
Right arrow Articles by Rosen, N.
Related Collections
Right arrowCommentary
Clinical Cancer Research Vol. 8, 986-993, May 2002
© 2002 American Association for Cancer Research

Advances in Brief

17-Allylamino-17-demethoxygeldanamycin Induces the Degradation of Androgen Receptor and HER-2/neu and Inhibits the Growth of Prostate Cancer Xenografts1

David B. Solit, Fuzhong F. Zheng, Maria Drobnjak, Pamela N. Münster, Brian Higgins2, David Verbel, Glenn Heller, William Tong, Carlos Cordon-Cardo, David B. Agus3, Howard I. Scher and Neal Rosen4

Program in Cell Biology [D. B. S., F. F. Z., P. N. M., N. R.], and Departments of Medicine [D. B. S., B. H., D. B. A., H. I. S., N. R.], Pathology [M. D., C. C-C.], and Epidemiology and Biostatistics [D. V., G. H.], Memorial Sloan-Kettering Cancer Center, New York, New York 10021

Purpose: Ansamycin antibiotics, including 17allylamino-17-demethoxygeldanamycin (17-AAG), inhibit Hsp90 function and cause the selective degradation of signaling proteins that require this chaperone for folding. Because mutations in the androgen receptor (AR) and activation of HER2 and Akt may account, in part, for prostate cancer progression after castration or treatment with antiandrogens, we sought to determine whether an inhibitor of Hsp90 function could degrade these Hsp90 client proteins and inhibit the growth of prostate cancer xenografts with an acceptable therapeutic index.

Experimental Design: The effect of 17-AAG on the expression of Hsp90 regulated signaling proteins in prostate cancer cells and xenografts was determined. The pharmacodynamics of target protein degradation was associated with the toxicology and antitumor activity of the drug.

Results: 17-AAG caused the degradation of HER2, Akt, and both mutant and wild-type AR and the retinoblastoma-dependent G1 growth arrest of prostate cancer cells. At nontoxic doses, 17-AAG caused a dose-dependent decline in AR, HER2, and Akt expression in prostate cancer xenografts. This decline was rapid, with a 97% loss of HER2 and an 80% loss of AR expression at 4 h. 17-AAG treatment at doses sufficient to induce AR, HER2, and Akt degradation resulted in the dose-dependent inhibition of androgen-dependent and -independent prostate cancer xenograft growth without toxicity.

Conclusions: These data demonstrate that, at a tolerable dose, inhibition of Hsp90 function by 17-AAG results in a marked reduction in HER2, AR, and Akt expression and inhibition of prostate tumor growth in mice. These results suggest that this drug may represent a new strategy for the treatment of prostate cancer.


Commentary

Heat Shock Protein 90 Inhibition by 17-Allylamino-17- demethoxygeldanamycin: A Novel Therapeutic Approach for Treating Hormone-refractory Prostate Cancer : Commentary re: D. B. Solit et al., 17-Allylamino-17-demethoxygeldanamycin Induces the Degradation of Androgen Receptor and Her-2/neu and Inhibits the Growth of Prostate Cancer Xenografts. Clin. Cancer Res., 8: 986–993, 2002.
Len Neckers
Clin. Cancer Res. 2002 8: 962-966. [Full Text] [PDF]



This article has been cited by other articles:


Home page
 Proc. Natl. Acad. Sci. USAHome page
E. Caldas-Lopes, L. Cerchietti, J. H. Ahn, C. C. Clement, A. I. Robles, A. Rodina, K. Moulick, T. Taldone, A. Gozman, Y. Guo, et al.
Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models
PNAS, May 19, 2009; 106(20): 8368 - 8373.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
K. Lundgren, H. Zhang, J. Brekken, N. Huser, R. E. Powell, N. Timple, D. J. Busch, L. Neely, J. L. Sensintaffar, Y.-c. Yang, et al.
BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90
Mol. Cancer Ther., April 1, 2009; 8(4): 921 - 929.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
Y. Okawa, T. Hideshima, P. Steed, S. Vallet, S. Hall, K. Huang, J. Rice, A. Barabasz, B. Foley, H. Ikeda, et al.
SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK
Blood, January 22, 2009; 113(4): 846 - 855.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
A. Yano, S. Tsutsumi, S. Soga, M.-J. Lee, J. Trepel, H. Osada, and L. Neckers
Inhibition of Hsp90 activates osteoclast c-Src signaling and promotes growth of prostate carcinoma cells in bone
PNAS, October 7, 2008; 105(40): 15541 - 15546.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
P Singh, A Uzgare, I Litvinov, S R Denmeade, and J T Isaacs
Combinatorial androgen receptor targeted therapy for prostate cancer.
Endocr. Relat. Cancer, September 1, 2006; 13(3): 653 - 666.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
W. A. Weber
Chaperoning Drug Development with PET
J. Nucl. Med., May 1, 2006; 47(5): 735 - 737.
[Full Text] [PDF]

Home page
 JNMHome page
P. M. Smith-Jones, D. Solit, F. Afroze, N. Rosen, and S. M. Larson
Early Tumor Response to Hsp90 Therapy Using HER2 PET: Comparison with 18F-FDG PET
J. Nucl. Med., May 1, 2006; 47(5): 793 - 796.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
C. S. Mitsiades, N. S. Mitsiades, C. J. McMullan, V. Poulaki, A. L. Kung, F. E. Davies, G. Morgan, M. Akiyama, R. Shringarpure, N. C. Munshi, et al.
Antimyeloma activity of heat shock protein-90 inhibition
Blood, February 1, 2006; 107(3): 1092 - 1100.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. da Rocha Dias, F. Friedlos, Y. Light, C. Springer, P. Workman, and R. Marais
Activated B-RAF Is an Hsp90 Client Protein That Is Targeted by the Anticancer Drug 17-Allylamino-17-Demethoxygeldanamycin
Cancer Res., December 1, 2005; 65(23): 10686 - 10691.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
U. Banerji, M. Walton, F. Raynaud, R. Grimshaw, L. Kelland, M. Valenti, I. Judson, and P. Workman
Pharmacokinetic-Pharmacodynamic Relationships for the Heat Shock Protein 90 Molecular Chaperone Inhibitor 17-Allylamino, 17-Demethoxygeldanamycin in Human Ovarian Cancer Xenograft Models
Clin. Cancer Res., October 1, 2005; 11(19): 7023 - 7032.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
L. Chen, S. Meng, H. Wang, P. Bali, W. Bai, B. Li, P. Atadja, K. N. Bhalla, and J. Wu
Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824
Mol. Cancer Ther., September 1, 2005; 4(9): 1311 - 1319.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. Shimamura, A. M. Lowell, J. A. Engelman, and G. I. Shapiro
Epidermal Growth Factor Receptors Harboring Kinase Domain Mutations Associate with the Heat Shock Protein 90 Chaperone and Are Destabilized following Exposure to Geldanamycins
Cancer Res., July 15, 2005; 65(14): 6401 - 6408.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
Y. Zhang, X.-W. Wang, D. Jelovac, T. Nakanishi, M.-h. Yu, D. Akinmade, O. Goloubeva, D. D. Ross, A. Brodie, and A. W. Hamburger
The ErbB3-binding protein Ebp1 suppresses androgen receptor-mediated gene transcription and tumorigenesis of prostate cancer cells
PNAS, July 12, 2005; 102(28): 9890 - 9895.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. K. Schwartz
Development of Cell Cycle Active Drugs for the Treatment of Gastrointestinal Cancers: A New Approach to Cancer Therapy
J. Clin. Oncol., July 10, 2005; 23(20): 4499 - 4508.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
U. Banerji, A. O'Donnell, M. Scurr, S. Pacey, S. Stapleton, Y. Asad, L. Simmons, A. Maloney, F. Raynaud, M. Campbell, et al.
Phase I Pharmacokinetic and Pharmacodynamic Study of 17-Allylamino, 17-Demethoxygeldanamycin in Patients With Advanced Malignancies
J. Clin. Oncol., June 20, 2005; 23(18): 4152 - 4161.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
Z Culig, H Steiner, G Bartsch, and A Hobisch
Mechanisms of endocrine therapy-responsive and -unresponsive prostate tumours
Endocr. Relat. Cancer, June 1, 2005; 12(2): 229 - 244.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. T. Price, J. M.W. Quinn, N. A. Sims, J. Vieusseux, K. Waldeck, S. E. Docherty, D. Myers, A. Nakamura, M. C. Waltham, M. T. Gillespie, et al.
The Heat Shock Protein 90 Inhibitor, 17-Allylamino-17-demethoxygeldanamycin, Enhances Osteoclast Formation and Potentiates Bone Metastasis of a Human Breast Cancer Cell Line
Cancer Res., June 1, 2005; 65(11): 4929 - 4938.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
X. Yin, H. Zhang, F. Burrows, L. Zhang, and C. G. Shores
Potent Activity of a Novel Dimeric Heat Shock Protein 90 Inhibitor against Head and Neck Squamous Cell Carcinoma In vitro and In vivo
Clin. Cancer Res., May 15, 2005; 11(10): 3889 - 3896.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. K. Ramanathan, D. L. Trump, J. L. Eiseman, C. P. Belani, S. S. Agarwala, E. G. Zuhowski, J. Lan, D. M. Potter, S. P. Ivy, S. Ramalingam, et al.
Phase I Pharmacokinetic-Pharmacodynamic Study of 17-(Allylamino)-17-Demethoxygeldanamycin (17AAG, NSC 330507), a Novel Inhibitor of Heat Shock Protein 90, in Patients with Refractory Advanced Cancers
Clin. Cancer Res., May 1, 2005; 11(9): 3385 - 3391.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T.-L. Cha, L. Qiu, C.-T. Chen, Y. Wen, and M.-C. Hung
Emodin Down-Regulates Androgen Receptor and Inhibits Prostate Cancer Cell Growth
Cancer Res., March 15, 2005; 65(6): 2287 - 2295.
[Abstract] [Full Text] [PDF]

Home page
 Cold Spring Harb Symp Quant BiolHome page
R. BENEZRA, E. HENKE, A. CIARROCCHI, M. RUZINOVA, D. SOLIT, N. ROSEN, D. NOLAN, V. MITTAL, and P. DE CANDIA
Induction of Complete Regressions of Oncogene-induced Breast Tumors in Mice
Cold Spring Harb Symp Quant Biol, January 1, 2005; 70(0): 375 - 381.
[Abstract] [PDF]

Home page
 Integr Cancer TherHome page
M. F. McCarty
Targeting Multiple Signaling Pathways as a Strategy for Managing Prostate Cancer: Multifocal Signal Modulation Therapy
Integr Cancer Ther, December 1, 2004; 3(4): 349 - 380.
[Abstract] [PDF]

Home page
 Endocr Relat CancerHome page
H. I Scher, G. Buchanan, W. Gerald, L. M Butler, and W. D Tilley
Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer
Endocr. Relat. Cancer, September 1, 2004; 11(3): 459 - 476.
[Abstract] [Full Text] [PDF]

Home page
 J Biomol ScreenHome page
J. Kim, S. Felts, L. Llauger, H. He, H. Huezo, N. Rosen, and G. Chiosis
Development of a Fluorescence Polarization Assay for the Molecular Chaperone Hsp90
J Biomol Screen, August 1, 2004; 9(5): 375 - 381.
[Abstract] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
R. Bagatell and L. Whitesell
Altered Hsp90 function in cancer: A unique therapeutic opportunity
Mol. Cancer Ther., August 1, 2004; 3(8): 1021 - 1030.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
S. M. Larson, M. Morris, I. Gunther, B. Beattie, J. L. Humm, T. A. Akhurst, R. D. Finn, Y. Erdi, K. Pentlow, J. Dyke, et al.
Tumor Localization of 16{beta}-18F-Fluoro-5{alpha}-Dihydrotestosterone Versus 18F-FDG in Patients with Progressive, Metastatic Prostate Cancer
J. Nucl. Med., March 1, 2004; 45(3): 366 - 373.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
S. K. Kulp, Y.-T. Yang, C.-C. Hung, K.-F. Chen, J.-P. Lai, P.-H. Tseng, J. W. Fowble, P. J. Ward, and C.-S. Chen
3-Phosphoinositide-Dependent Protein Kinase-1/Akt Signaling Represents a Major Cyclooxygenase-2-Independent Target for Celecoxib in Prostate Cancer Cells
Cancer Res., February 15, 2004; 64(4): 1444 - 1451.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. I. Scher, M. Eisenberger, A. V. D'Amico, S. Halabi, E. J. Small, M. Morris, M. W. Kattan, M. Roach, P. Kantoff, K. J. Pienta, et al.
Eligibility and Outcomes Reporting Guidelines for Clinical Trials for Patients in the State of a Rising Prostate-Specific Antigen: Recommendations From the Prostate-Specific Antigen Working Group
J. Clin. Oncol., February 1, 2004; 22(3): 537 - 556.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
W. C. S. Cho, T. T. C. Yip, C. Yip, V. Yip, V. Thulasiraman, R. K. C. Ngan, T.-T. Yip, W.-H. Lau, J. S. K. Au, S. C. K. Law, et al.
Identification of Serum Amyloid A Protein As a Potentially Useful Biomarker to Monitor Relapse of Nasopharyngeal Cancer by Serum Proteomic Profiling
Clin. Cancer Res., January 1, 2004; 10(1): 43 - 52.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. Enmon, W.-H. Yang, A. M. Ballangrud, D. B. Solit, G. Heller, N. Rosen, H. I. Scher, and G. Sgouros
Combination Treatment with 17-N-Allylamino-17-Demethoxy Geldanamycin and Acute Irradiation Produces Supra-Additive Growth Suppression in Human Prostate Carcinoma Spheroids
Cancer Res., December 1, 2003; 63(23): 8393 - 8399.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Rahmani, C. Yu, Y. Dai, E. Reese, W. Ahmed, P. Dent, and S. Grant
Coadministration of the Heat Shock Protein 90 Antagonist 17-Allylamino- 17-demethoxygeldanamycin with Suberoylanilide Hydroxamic Acid or Sodium Butyrate Synergistically Induces Apoptosis in Human Leukemia Cells
Cancer Res., December 1, 2003; 63(23): 8420 - 8427.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. Radiol.Home page
B M Seddon and P Workman
The role of functional and molecular imaging in cancer drug discovery and development
Br. J. Radiol., December 1, 2003; 76(suppl_2): S128 - S138.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
V. Poulaki, C. S. Mitsiades, C. McMullan, D. Sykoutri, G. Fanourakis, V. Kotoula, S. Tseleni-Balafouta, D. A. Koutras, and N. Mitsiades
Regulation of Vascular Endothelial Growth Factor Expression by Insulin-Like Growth Factor I in Thyroid Carcinomas
J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5392 - 5398.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Beliakoff, R. Bagatell, G. Paine-Murrieta, C. W. Taylor, A. E. Lykkesfeldt, and L. Whitesell
Hormone-Refractory Breast Cancer Remains Sensitive to the Antitumor Activity of Heat Shock Protein 90 Inhibitors
Clin. Cancer Res., October 15, 2003; 9(13): 4961 - 4971.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. S. Russell, W. Burgan, K. A. Oswald, K. Camphausen, and P. J. Tofilon
Enhanced Cell Killing Induced by the Combination of Radiation and the Heat Shock Protein 90 Inhibitor 17-Allylamino-17- Demethoxygeldanamycin: A Multitarget Approach to Radiosensitization
Clin. Cancer Res., September 1, 2003; 9(10): 3749 - 3755.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
W. Jia, C. Yu, M. Rahmani, G. Krystal, E. A. Sausville, P. Dent, and S. Grant
Synergistic antileukemic interactions between 17-AAG and UCN-01 involve interruption of RAF/MEK- and AKT-related pathways
Blood, September 1, 2003; 102(5): 1824 - 1832.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. P. Goetz, D. O. Toft, M. M. Ames, and C. Erlichman
The Hsp90 chaperone complex as a novel target for cancer therapy
Ann. Onc., August 1, 2003; 14(8): 1169 - 1176.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
I. V. Litvinov, A. M. De Marzo, and J. T. Isaacs
Is the Achilles' Heel for Prostate Cancer Therapy a Gain of Function in Androgen Receptor Signaling?
J. Clin. Endocrinol. Metab., July 1, 2003; 88(7): 2972 - 2982.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
D. B. Solit, A. D. Basso, A. B. Olshen, H. I. Scher, and N. Rosen
Inhibition of Heat Shock Protein 90 Function Down-Regulates Akt Kinase and Sensitizes Tumors to Taxol
Cancer Res., May 1, 2003; 63(9): 2139 - 2144.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2002 by the American Association for Cancer Research.